AGENUS INC Cash Equivalents, at Carrying Value
AGENUS INC (AGEN) had Cash Equivalents, at Carrying Value of $70.50 million as of 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashEquivalentsAtCarryingValue · last filed 2024-03-14
- 2023-12-31: Cash Equivalents, at Carrying Value $70.50M.
- 2023-06-30: Cash Equivalents, at Carrying Value $127.00M.
- 2023-03-31: Cash Equivalents, at Carrying Value $143.80M.
- 2022-12-31: Cash Equivalents, at Carrying Value $164.70M.
| Period end | Cash Equivalents, at Carrying Value |
|---|---|
| 2023-12-31 | $70.50M 10-K · filed 2024-03-14 |
| 2023-06-30 | $127.00M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $143.80M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $164.70M 10-K · filed 2024-03-14 |
| 2022-09-30 | $190.10M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $212.90M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $228.20M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $239.90M 10-K · filed 2023-03-16 |
| 2021-09-30 | $242.80M 10-Q · filed 2021-11-09 |
| 2018-03-31 | $50.90M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $57.00M 10-Q · filed 2018-05-10 |
| 2017-09-30 | $63.70M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $80.60M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $111.80M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $48.90M 10-K · filed 2018-03-16 |
| 2016-09-30 | $53.30M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $67.40M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $71.30M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $126.40M 10-K · filed 2017-03-16 |
| 2015-09-30 | $172.80M 10-Q · filed 2015-11-04 |
| 2014-12-31 | $25.10M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |